These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Drug safety. FDA panel urges caution on many anti-inflammatory drugs. Couzin J Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414 [No Abstract] [Full Text] [Related]
3. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions]. Bolten WW; Reiter S; Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092 [No Abstract] [Full Text] [Related]
4. Raising the safety bar--the FDA's coxib meeting. Okie S N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221 [No Abstract] [Full Text] [Related]
5. Cardiovascular toxicity of valdecoxib. Ray WA; Griffin MR; Stein CM N Engl J Med; 2004 Dec; 351(26):2767. PubMed ID: 15608086 [No Abstract] [Full Text] [Related]
7. Serious dermatologic reaction associated with valdecoxib: report of two cases. Knowles SR; Phillips EJ; Wong G; Shear NH J Am Acad Dermatol; 2004 Dec; 51(6):1028-9. PubMed ID: 15583610 [No Abstract] [Full Text] [Related]
8. COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions? Bannwarth B Expert Opin Drug Saf; 2006 Jan; 5(1):1-2; author reply 1-2. PubMed ID: 16370948 [No Abstract] [Full Text] [Related]
9. How celecoxib could be safer, how valdecoxib might have been. Cohen JS Ann Pharmacother; 2005 Sep; 39(9):1542-5. PubMed ID: 16076909 [TBL] [Abstract][Full Text] [Related]
10. Arthritis medicines and cardiovascular events--"house of coxibs". Topol EJ JAMA; 2005 Jan; 293(3):366-8. PubMed ID: 15623849 [No Abstract] [Full Text] [Related]
12. Valdecoxib (Bextra)--a new cox-2 inhibitor. Med Lett Drugs Ther; 2002 Apr; 44(1129):39-40. PubMed ID: 11981510 [No Abstract] [Full Text] [Related]
13. [Current EULAR data on valdecoxib. New study results of gastrointestinal safety and "cost effectiveness"]. Kellner H Krankenpfl J; 2004; 42(5-6):185. PubMed ID: 15527245 [No Abstract] [Full Text] [Related]
14. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). Cotter J; Wooltorton E CMAJ; 2005 May; 172(10):1299. PubMed ID: 15833921 [No Abstract] [Full Text] [Related]
15. [Progress in therapy of rheumatism. New coxib works especially fast]. MMW Fortschr Med; 2003 Jun; 145(23):58. PubMed ID: 12854230 [No Abstract] [Full Text] [Related]
16. Cox-2 inhibitors: still no decisive action. Prescrire Int; 2005 Jun; 14(77):102. PubMed ID: 15981408 [TBL] [Abstract][Full Text] [Related]
17. The COX-2 inhibitors--an update. Furberg CD Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896 [No Abstract] [Full Text] [Related]
18. Rescuing COX-2 inhibitors from the waste bin. Albini A; Noonan DM J Natl Cancer Inst; 2005 Jun; 97(11):859-60. PubMed ID: 15928309 [No Abstract] [Full Text] [Related]
19. FDA ponders future of NSAIDs: Pfizer reluctantly withdraws Bextra. Young D Am J Health Syst Pharm; 2005 May; 62(10):997, 1000. PubMed ID: 15901579 [No Abstract] [Full Text] [Related]